USA flag logo/image

An Official Website of the United States Government

Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
U44NS071657
Solicitation Year:
2011
Solicitation Topic Code:
NINDS
Solicitation Number:
PAR08-235
Small Business Information
NEUROP, INC.
58 Edgewood Road ATLANTA, GA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme
Agency: HHS
Contract: 1U44NS071657-01A1
Award Amount: $299,541.00
 

Abstract:

DESCRIPTION (provided by applicant): Cerebral ischemia is a major cause of death and long-term disability, with high accompanying social and medical costs. Approximately 795,000 Americans suffer a stroke each year at an estimated annual cost of 73.7B (American Heart Association. Heart Disease and Stroke Statistics, 2010 Update). Substantial preclinical data support the use of NMDA receptor antagonists to reduce brain damage caused by cerebral ischemia. However, to date no drug acting through this target has been successful in clinical trials of cerebral ischemia, largely due to two issues: i) adverse effects that prevented attaining drug levels adequate for efficacy, and ii) clinical restraints that prevented drug administration within the short time afterischemia required for efficacy. We are using a multi-pronged strategy to overcome these obstacles in the development of a context-dependent, pH-sensitive, NR2B subunit selective NMDA receptor antagonist for prophylactic use in subarachnoid hemorrhage (SAH). SAH patients are at substantial risk of experiencing a stroke-like ischemic event four to 14 days after their surgery to coil or clip their aneurysm. NR2B selective antagonists are intrinsically better tolerated than early generations of non-selective NMDA antagonists. Furthermore, our medicinal chemistry and pharmacology group has discovered and optimized compounds selective for NR2B receptor inhibition that are more potent at the interstitial acidic pH characteristic of the penumbral region in focal ischemia than non-ischemic tissue. More importantly, the relative lack of NMDA receptor block in non- ischemic, healthy tissues at physiological pH minimizes the potential for on-target cognitive and psychotomimetic adverse effects that have limited prior drug candidates. Because of the context-dependent, penumbral-selective actions of our compounds, we anticipate a dramatic improvement in drug tolerability, allowing for prophylactic administration prior to ischemia during the 14 days after aneurysm surgery inSAH patients. Thus, our IND candidate will be available for neuroprotective NMDA receptor block at the site of, and earliest onset of, secondary ischemia. The work proposed here is aimed at identifying a novel neuroprotective agent suitable for prophylactic use by taking advantage of coupling pH-dependent receptor block with the intrinsic efficacy and tolerability of NR2B-selective NMDA receptor blockade. PUBLIC HEALTH RELEVANCE: Cerebral ischemia describes many conditions in which there is inadequate blood supply to the brain. Cerebral ischemia may be caused by stroke, traumatic brain injury or may happen during cardiovascular surgery. It is a significant cause of death and disability. There are no drugs approved that protect brain tissue from ischemia- induced damage. We propose to develop a novel drug to protect the brain from damage caused by cerebral ischemia.

Principal Investigator:

George W. Koszalka
404-941-2360
bkoszalka@neuropinc.com

Business Contact:

George B. Kosxalka
404-941-2360
bkoszalka@neuropinc.com
Small Business Information at Submission:

NEUROP, INC.
58 Edgewood Road ATLANTA, GA -

EIN/Tax ID: 103044181
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No